BRPI0908861A2 - vitrified sugar virus-like particles (vlps) - Google Patents

vitrified sugar virus-like particles (vlps)

Info

Publication number
BRPI0908861A2
BRPI0908861A2 BRPI0908861A BRPI0908861A BRPI0908861A2 BR PI0908861 A2 BRPI0908861 A2 BR PI0908861A2 BR PI0908861 A BRPI0908861 A BR PI0908861A BR PI0908861 A BRPI0908861 A BR PI0908861A BR PI0908861 A2 BRPI0908861 A2 BR PI0908861A2
Authority
BR
Brazil
Prior art keywords
vlps
vitrified
virus
sugar
particles
Prior art date
Application number
BRPI0908861A
Other languages
Portuguese (pt)
Inventor
Shenoy Dinesh
Robinson James
Original Assignee
Novavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novavax Inc filed Critical Novavax Inc
Publication of BRPI0908861A2 publication Critical patent/BRPI0908861A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16023—Virus like particles [VLP]
BRPI0908861A 2008-02-25 2009-02-25 vitrified sugar virus-like particles (vlps) BRPI0908861A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3124308P 2008-02-25 2008-02-25
PCT/US2009/035122 WO2009108689A1 (en) 2008-02-25 2009-02-25 Sugar glassified virus like particles (vlps)

Publications (1)

Publication Number Publication Date
BRPI0908861A2 true BRPI0908861A2 (en) 2018-02-06

Family

ID=41016454

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908861A BRPI0908861A2 (en) 2008-02-25 2009-02-25 vitrified sugar virus-like particles (vlps)

Country Status (8)

Country Link
EP (1) EP2254554A1 (en)
JP (1) JP2011514337A (en)
CN (1) CN102014873A (en)
BR (1) BRPI0908861A2 (en)
CA (1) CA2716546A1 (en)
MX (1) MX2010009351A (en)
RU (1) RU2010139478A (en)
WO (1) WO2009108689A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE051666T2 (en) 2008-12-09 2021-03-29 Novavax Inc Modified rsv f proteins and methods of their use
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
US20130028933A1 (en) * 2009-12-28 2013-01-31 Ligocyte Pharmaceuticals, Inc. Methods for stabilizing influenza antigen enveloped virus-based virus-like particle solutions
GB201002419D0 (en) * 2010-02-12 2010-03-31 Isis Innovation Stable live vaccine formulations
CA2819236A1 (en) * 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Lyophilized viral formulations
WO2012075379A2 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Liquid viral formulations
CA2834618C (en) 2011-06-24 2020-11-03 Merck Sharp & Dohme Corp. Hpv vaccine formulations comprising aluminum adjuvant and methods of producing same
CN104080476A (en) * 2011-09-30 2014-10-01 诺瓦瓦克斯股份有限公司 Recombinant nanoparticle RSV F vaccine for respiratory syncytial virus
US20130089638A1 (en) * 2011-10-11 2013-04-11 Mead Johnson Nutrition Company Compositions Comprising Maltotriose And Methods Of Using Same To Inhibit Damage Caused By Dehydration Processes
US10736840B2 (en) 2013-09-03 2020-08-11 Georgia Tech Research Corporation Thermally stable vaccine formulations and microneedles
US9649279B2 (en) 2013-12-16 2017-05-16 Massachusetts Institute Of Technology Fortified micronutrient salt formulations
EP3082852B1 (en) 2013-12-16 2020-06-17 Massachusetts Institute of Technology Micromolded or 3-d printed pulsatile release vaccine formulations
EA201691348A1 (en) * 2013-12-31 2016-11-30 Инфекшес Дизиз Рисерч Инститьют ONE-FLAKE VACCINE COMPOSITIONS
US11273127B2 (en) 2014-05-06 2022-03-15 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for thermally stable multi-targeted antigens
US20170065707A1 (en) * 2014-05-06 2017-03-09 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for thermally stable human papillomavirus formulations
CN114796474A (en) 2015-09-03 2022-07-29 诺瓦瓦克斯股份有限公司 Vaccine compositions with improved stability and immunogenicity
KR20200000497A (en) * 2015-09-04 2020-01-02 인벤트프라이즈 엘엘씨 Vlp stabilized vaccine compositions
AU2019238171A1 (en) 2018-03-19 2020-09-24 Novavax, Inc. Multivalent influenza nanoparticle vaccines
CA3141577A1 (en) * 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
GB9705588D0 (en) * 1997-03-18 1997-05-07 Anglia Research Foundation Stable particle in liquid formulations
EP1599186B1 (en) * 2003-02-24 2013-04-10 Pharmaceutical Productions Inc. Transmucosal drug delivery system
GB0409795D0 (en) * 2004-04-30 2004-06-09 Glaxosmithkline Biolog Sa Drying method
US7871632B2 (en) * 2004-07-12 2011-01-18 Adventrx Pharmaceuticals, Inc. Compositions for delivering highly water soluble drugs
GB0502661D0 (en) * 2005-02-09 2005-03-16 Stabilitech Ltd A desiccated product
MY139088A (en) * 2005-02-21 2009-08-28 Lg Life Sciences Ltd Sustained release composition of protein drug

Also Published As

Publication number Publication date
EP2254554A1 (en) 2010-12-01
MX2010009351A (en) 2011-03-04
JP2011514337A (en) 2011-05-06
RU2010139478A (en) 2012-05-20
WO2009108689A1 (en) 2009-09-03
CA2716546A1 (en) 2009-09-03
CN102014873A (en) 2011-04-13

Similar Documents

Publication Publication Date Title
BRPI0908861A2 (en) vitrified sugar virus-like particles (vlps)
IL210215A0 (en) Influenza virus-like particles (vlps) comprising hemagglutinin
DK2049559T3 (en) Improved HPV vaccines
IL193566A0 (en) Hpv-18-based papillomavirus vaccine
ZA201001480B (en) Method for producing flu virus
EP2044198A4 (en) Chimeric influenza virus-like particles
IL237406A0 (en) Improved methods for producing yeast-based vaccines
PL2173376T3 (en) Multimeric multiepitope influenza vaccines
RS56157B1 (en) Rabies glycoprotein virus-like particles (vlps)
EP2062246A4 (en) Chimeric virus vaccines
IL193661A0 (en) Papillomavirus vaccine
IL211184A0 (en) Polyvalent vaccine
GB0807424D0 (en) Virus
EP2241626A4 (en) Baculovirus-based vaccines
ZA201201137B (en) Antigen specific multi epitope-based anti-infective vaccines
ZA201100962B (en) Influenza vaccines
ZA201100889B (en) Vaccine against hpv
GB0706912D0 (en) Novel viral vaccines
GB2459863B (en) Mems transducers
GB0823560D0 (en) Virus
ZA200808893B (en) HPV-16-Based Papillomavirus vaccine
IL226187B (en) Rabies glycoprotein virus-like particles (vlps)
GB0818459D0 (en) Vaccines
GB0813823D0 (en) Virus
GB0810378D0 (en) Virus

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)